Search

5-O-phosphono-alpha-D-ribofuranosyl diphosphate

The key substance in the biosynthesis of histidine, tryptophan, and purine and pyrimidine nucleotides.

Ragweed pollen extract

The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy.

Brasofensine

Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K. … In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.

Iohexol

Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.

MC-1

Medicure's MC-1 drug is a cardio-protectant, designed to reduce the damage to the heart when arteries are blocked and when they are subsequently reopened after bypass surgery.

Lonoctocog alfa

Lancovutide

Lancovutide is a 19-amino-acid tetracyclic peptide produced by Streptoverticillium cinnamoneus and is closely related to cinnamycin (Ro09-0198). It belongs to the lantibiotics. … Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis.

IR501

It was last known to be in phase III clinical trials. … IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity.

Ezatiostat

This compound belongs to the peptides. … These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen

Surotomycin

Difficile and other Gram-positive bacteria with minimal impact on the Gram-negative organisms of the intestinal microbiota. … Surotomycin, given orally, has been shown to be highly effective against both initial and relapsing hamster Clostridium difficile-associated diarrhea, with a potency similar to vancomycin.